Enterprise Value

4.933B

Cash

414.1M

Avg Qtr Burn

N/A

Short % of Float

7.49%

Insider Ownership

2.81%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PYLARIFY Details
Prostate cancer, Cancer

Approved

Quarterly sales

RELISTOR Details
Constipation

Approved

Quarterly sales

DEFINITY® Room Temperature Details
Suboptimal echocardiograms

Approved

Quarterly sales

AZEDRA® (iobenguane I 131) Details
Pheochromocytoma , Paraganglioma , Solid tumor/s

Approved

Quarterly sales

¹⁷⁷Lu-PNT2002 Details
Cancer, Castration-resistant prostate cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

Flurpiridaz F 18 Details
Heart disease, Coronary artery disease

Phase 3

Update

Phase 2

Data readout

LNTH-1404 Details
Prostate cancer, Cancer

Failed

Discontinued